Recommendations for the use of methotrexate in juvenile idiopathic arthritis

Pediatric Drugs

Volumn 8, Issue 6, 2006, Pages 347-356

  Niehues, Tim ^a,b   Lankisch, Petra ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Jeffrey Modell Immunodeficiency Centre   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYMETHOTREXATE; AURANOFIN; BARBITURIC ACID DERIVATIVE; CELECOXIB; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; CYTOKINE RECEPTOR ANTAGONIST; DIMENHYDRINATE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FOLIC ACID; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METOCLOPRAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; ONDANSETRON; ORAL CONTRACEPTIVE AGENT; PENICILLAMINE; PENICILLIN DERIVATIVE; PHENYTOIN; PLACEBO; ROFECOXIB; TETRACYCLINE; TRANQUILIZER; TROPISETRON; UNINDEXED DRUG;

AMINOTRANSFERASE BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; APHTHOUS ULCER; ARTHRITIS; AVERSION; BLOOD TOXICITY; BONE MARROW APLASIA; BONE MARROW SUPPRESSION; BRAIN TOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG UPTAKE; DRUG USE; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HODGKIN DISEASE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMPOTENCE; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; LABORATORY TEST; LEUKOPENIA; LIVER FIBROSIS; LIVER TOXICITY; LOW DRUG DOSE; LUNG TOXICITY; MALFORMATION SYNDROME; MEDICAL LITERATURE; MEGALOCYTOSIS; META ANALYSIS; MONOTHERAPY; MOUTH ULCER; NAUSEA; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; OLIGOSPERMIA; PHYSIOTHERAPY; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REMISSION; REVIEW; SIDE EFFECT; SKIN ALTERATION; SKIN DISEASE; SYSTEMATIC REVIEW; TERATOGENICITY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TUMOR; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLIC ACID; HUMANS; INFANT; METHOTREXATE; TREATMENT OUTCOME;

EID: 33845496499     PISSN: 11745878     EISSN: 11745878     Source Type: Journal    
DOI: 10.2165/00148581-200608060-00003     Document Type: Review

References (96)

1. Cassidy JT, Petty R. Textbook of pediatric rheumatology. 4th ed. Philadelphia (PA): WB Saunders Company, 2001
2. Wahn V, Oppermann J, Huppertz HI, et al. Rheumatische Erkrankungen im Kindes- und Jugendalter. Hans Marseille Verlag 2001; 1: 156
3. Minden K, Niewerth M, Listing J, et al. German Study Group of Pediatric Rheumatologists: health care provision in pediatric rheumatology in Germany: national rheumatologic database. J Rheumatol 2002 Mar; 29 (3): 622-8
4. Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2005 Feb; 32: 362-5
5. Ramanan AV, Withworth P, Baildam EM. Use of methotrexate in juvenile idiopathic arthritis. Arch Dis Child 2003; 88: 197-200
6. Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum 2004; 50: 1370-82
7. Hou Z, Stapels SE, Haska CL, et al. Localization of a substrate binding domain of the human reduced folate carrier to transmembrane domain 11 by radioaffinity labeling and cysteine-substituted accessibility methods. J Biol Chem 2005; 280: 36206-13
8. Dolezalova P, Krijt J, Chladek J, et al. Adenosine and methotrexate polyglutamate concentrations in patients with juvenile arthritis. Rheumatology 2005; 44: 74-9
9. Johnston A, Gudjonsson JE, Sigmundsdottir H, et al. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 2005; 114: 154-63
10. Onel KB. Advances in the medical treatment of juvenile rheumatoid arthritis. Curr Opin Pediatr 2000; 12: 72-5
11. Seeliger S, Niehues T, Harms E, et al. Methotrexate in der Behandlung der juvenilen idiopathischen arthritis. Monatsschr Kinderheilkd 2002; 150: 452-9
12. Niehues T, Horneff G, Michels H, et al. Evidence-based use of methotrexate in children with rheumatic diseases: a consensus statement of the Working Groups Pediatric Rheumatology Germany (AGKJR) and Pediatric Rheumatology Austria. Rheumatol Int 2005; 25: 169-78
13. Andersen PA, West SG, O'Dell JR, et al. Weekly pulse methotrexate in rheumatoid arthritis: clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med 1985; 103: 489-96
14. Thompson RN, Watts C, Edelman J, et al. A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Rheumatol 1984; 11: 760-3
15. Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312: 818-22
16. Williams HJ, Willkens RF, Samuelson Jr CO, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1985; 28: 721-30
17. Canadian Task Force on the Periodic Health Examination. Canadian guide to clinical preventive health care. Ottawa (ON): Canada Communication Group, 1994
18. U.S. Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Baltimore (MD): Williams and Wilkins, 1996
19. Feldmann W. Evidence-based pediatrics. 1st ed. Hamilton (ON): BC Decker, 2000
20. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn't. BMJ 1996; 13: 71-2
21. Truckenbrodt H, Hafner R. Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study. Arthritis Rheum 1986; 29: 801-7
22. Giannini EH, Cassidy JT, Brewer EJ, et al. Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis. Semin Arthritis Rheum 1993 Aug; 23: 34-46
23. Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis: results of the USA-USSR double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and the Cooperative Children's Study Group. N Engl J Med 1992; 326: 1043-9
24. Woo P, Southwood TR, Prieur AM, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000; 43: 1849-57
25. Takken T, Van der Net J, Helder PJ. Methotrexate for treating juvenile idiopathic arthritis. Cochrane Database Syst Rev 2001; (4): CD003129
26. Ravelli A, Viola S, Migliavacca D, et al. The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis. J Pediatr 1999; 135: 316-20
27. Silverman E, Spiegel L, Hawkins D, et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 2005 Apr; 352: 1655-66
28. Cassidy JT. Medical management of children with juvenile rheumatoid arthritis. Drugs 1999; 58: 831-50
29. Ravelli A, Martini A. Methotrexate in juvenile idiopathic arthritis: answers and questions. J Rheumatol 2000; 27: 1830-3
30. Breit W, Frosch M, Meyer U, et al. A subgroup-specific evaluation of the efficacy of intraarticular triamcinolone hexacetonide in juvenile chronic arthritis. J Rheumatol 2000; 27: 2696-702
31. Padeh S, Passwell JH. Intraarticular corticosteroid injection in the management of children with chronic arthritis. Arthritis Rheum 1998; 41: 1210-4
32. Brik R, Berkowitz D, Berant M. Duration of methotrexate treatment until partial and total remission of refractory juvenile rheumatoid arthritis. Ann Rheum Dis 1998; 57: 174-5
33. Huang JL. Methotrexate in the treatment of children with chronic arthritis: long-term observations of efficacy and safety. Br J Clin Pract 1996; 50: 311-4
34. Gottlieb BS, Keenan GF, Lu T, et al. Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis. Pediatrics 1997; 100: 994-7
35. Ravelli A, Viola S, Ramenghi B, et al. Frequency of relapse after discontinuation of methotrexate therapy for clinical remission in juvenile rheumatoid arthritis. J Rheumatol 1995; 22: 1574-6
36. Foell D, Frosch M, Schulze zur Wiesch A, et al. Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop? Ann Rheum Dis 2004; 63: 206-8
37. Ruperto N, Murray KJ, Gerloni V, et al. A randomized trial of methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004 Jul; 50: 2192-202
38. Kremer JM, Galivan J, Streckfuss A, et al. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients: association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 1986; 29: 832-5
39. Oguey D, Kolliker F, Gerber NJ, et al. Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1992; 35: 611-4
40. Wallace CA. The use of methotrexate in childhood rheumatic diseases. Arthritis Rheum 1998; 41: 381-91
41. Balis FM, Mirro Jr J, Reaman GH, et al. Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol 1988; 6: 1882-6
42. Balis FM, Savitch JL, Bleyer WA. Pharmacokinetics of oral methotrexate in children. Cancer Res 1983; 43: 2342-5
43. Alsufyani K, Ortiz-Alvarez O, Cabral DA, et al. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol 2004; 31: 179-82
44. Jundt JW, Browne BA, Fiocco GP, et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993; 20: 1845-9
45. Furst DE, Kremer JM. Methotrexate in rheumatoid arthritis. Arthritis Rheum 1988; 31: 305-14
46. Dupuis LL, Koren G, Silverman ED, et al. Influence of food on the bioavailability of oral methotrexate in children. J Rheumatol 1995; 22: 1570-3
47. O'Dell JR. Methotrexate use in rheumatoid arthritis. Rheum Dis Clin North Am 1997; 23: 779-96
48. Aherne GW, Piall E, Marks V, et al. Prolongation and enhancement of serum methotrexate concentrations by probenecid. BMJ 1978; 29: 1097-9
49. Albertioni F, Flato B, Seideman P, et al. Methotrexate in juvenile rheumatoid arthritis: evidence of age dependent pharmacokinetics. Eur J Clin Pharmacol 1995; 47: 507-11
50. Reiff A, Shaham B, Wood BP, et al. High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis. Clin Exp Rheumatol 1995; 13: 113-8
51. Wallace CA, Bleyer WA, Sherry DD, et al. Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis Rheum 1989; 32: 677-81
52. Morgan SL, Oster RA, Lee JY, et al. The effect of folic acid and folinic acid supplementation on purine metabolism in methotrexate-treated rheumatoid arthritis. Arthritis Rheum 2004; 50: 3104-11
53. Cronstein BN. Folic acid and folinic acid supplements and methotrexate therapy: comment on the article by Morgan, et al. Arthritis Rheum 2005 Apr; 52 (4): 1338-9
54. Ortiz Z, Shea B, Suarez-Almazor ME, et al. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis: a metaanalysis of randomized controlled trials. J Rheumatol 1998; 25: 36-43
55. van Ede AE, Laan RF, Rood MJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001; 44: 1515-24
56. Morgan SL, Baggott JE, Lee JY, et al. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during long term, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol 1998; 25: 441-6
57. van Ede AE, Laan RF, Blom HJ, et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatol (Oxf) 2002; 41: 658-65
58. Harten P. Folsäure zur Reduktion der Methotrexate-Toxiziẗat. Z Rheumatol 2005; 64: 353-8
59. Hunt PG, Rose CD, McIlvain-Simpson G, et al. The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis: a controlled study. J Rheumatol 1997; 24: 2230-2
60. Huemer M, Fodinger M, Huemer C, et al. Hyperhomocysteinemia in children with juvenile idiopathic arthritis is not influenced by methotrexate treatment and folic acid supplementation: a pilot study. Clin Exp Rheumatol 2003; 21: 249-55
61. Dupuis LL, Koren G, Shore A, et al. Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. J Rheumatol 1990; 17: 1469-73
62. Singsen BH, Goldbach-Mansky R. Methotrexate in the treatment of juvenile rheumatoid arthritis and other pediatric rheumatoid and nonrheumatic disorders. Rheum Dis Clin North Am 1997; 23: 811-40
63. Wallace CA, Smith AL, Sherry DD. Pilot investigation of naproxen/methotrexate interaction in patients with juvenile rheumatoid arthritis. J Rheumatol 1993; 20: 1764-8
64. Lafforgue P, Monjanel-Mouterde S, Durand A, et al. Is there an interaction between low doses of corticosteroids and methotrexate in patients with rheumatoid arthritis? A pharmacokinetic study in 33 patients. J Rheumatol 1993; 20: 263-7
65. O'Dell JR. Combinations of conventional disease-modifying antirheumatic drugs. Rheum Dis Clin North Am 2001; 27: 415-26
66. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9
67. Schmeling H, Mathony K, John V, et al. A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study. Ann Rheum Dis 2001; 60: 410-2
68. Gerloni V, Pontikaki I, Gattinara M, et al. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor α monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-labeled prospective study. Arthritis Rheum 2005 Feb; 52 (2): 548-53
69. Mariette X, Cazals-Hatem D, Warszawki J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002 Jun 1; 99: 3909-15
70. Ortiz-Alavarez O, Morishita K, Avery G, et al. Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol 2004; 31: 2501-6
71. Franke J, Hafner R, Lohrs U, et al. Methotrexate and liver fibrosis in juvenile chronic arthritis retrospective study of 73 liver biopsies. Monatschr Kinderheilkd 1996; 144: 147-51
72. Hashkes PJ, Balistreri WF, Bove KE, et al. The long-term effect of methotrexate therapy on the liver in patients with juvenile rheumatoid arthritis. Arthritis Rheum 1997; 40: 2226-34
73. Erickson AR, Reddy V, Vogelgesang SA, et al. Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients. Arthritis Rheum 1995; 38: 1115-9
74. Kremer JM, Alarcon GS, Lightfoot Jr RW, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994; 37: 316-28
75. Kremer JM, Alarcon GS, Weinblatt ME, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997; 40: 1829-37
76. Salaffi F, Manganelli P, Carotti M, et al. Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature. Clin Rheumatol 1997; 16: 296-304
77. Cron RQ, Sherry DD, Wallace CA. Methotrexate-induced hypersensitivity pneumonitis in a child with juvenile rheumatoid arthritis. J Pediatr 1998; 132: 901-2
78. Camiciottoli G, Trapani S, Castellani W, et al. Effect on lung function of methotrexate and non-steroid anti-inflammatory drugs in children with juvenile rheumatoid arthritis. Rheumatol Int 1998; 18: 11-6
79. Pelucchi A, Lomater C, Gerloni V, et al. Lung function and diffusing capacity for carbon monoxide in patients with juvenile chronic arthritis: effect of disease activity and low dose methotrexate therapy. Clin Exp Rheumatol 1994; 12: 675-9
80. Schmeling H, Stephan V, Burdach S, et al. Pulmonary function in children with juvenile idiopathic arthritis and effects of methotrexate therapy. Z Rheumatol 2002; 61: 168-72
81. Graham LD, Myones BL, Rivas-Chacon RF, et al. Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis. J Pediatr 1992; 120: 468-73
82. Kinder AJ, Hassell AB, Brand J, et al. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology 2005; 44: 61-6
83. Grennan DM, Gray J, Loudon J, et al. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 2001; 60: 214-7
84. McKendry RJ. The remarkable spectrum of methotrexate toxicities. Rheum Dis Clin North Am 1997; 23: 939-54
85. Rackham OJ, Sills JA, Davidson JE. Immunoglobulin levels in methotrexate treated paediatric rheumatology patients. Arch Dis Child 2002; 87: 147-8
86. Rau R. Treatment of chronic polyarthritis with methotrexate 1994: a review. Z Rheumatol 1994; 53: 199-229
87. Cleary AG, McDowell H, Sills JA. Polyarticular juvenile idiopathic arthritis treated with methotrexate complicated by the development of non-Hodgkin's lymphoma. Arch Dis Child 2002; 86: 47-9
88. Krugmann J, Sailer-Hock M, Muller T, et al. Epstein-Barr virus-associated Hodgkin's lymphoma and Legionella pneumophila infection complicating treatment of juvenile rheumatoid arthritis with methotrexate and cyclosporine A. Hum Pathol 2000; 31: 253-5
89. Londino Jr AV, Blatt J, Knisely AS. Hodgkin's disease in a patient with juvenile rheumatoid arthritis taking weekly low dose methotrexate. J Rheumatol 1998; 25: 1245-6
90. Munro R, Porter DR, Sturrock RD. Lymphadenopathy in a patient with systemic onset juvenile chronic arthritis. Ann Rheum Dis 1998; 57: 513-7
91. Padeh S, Sharon N, Schiby G, et al. Hodgkin's lymphoma in systemic onset juvenile rheumatoid arthritis after treatment with low dose methotrexate. J Rheumatol 1997; 24: 2035-7
92. Bawle EV, Conard JV, Weiss L. Adult and two children with fetal methotrexate syndrome. Teratology 1998; 57: 51-5
93. Kozlowski RD, Steinbrunner JV, MacKenzie AH, et al. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 1990; 88: 589-92
94. Buckley LM, Bullaboy CA, Leichtman L, et al. Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheum 1997; 40: 971-3
95. Blackburn Jr WD, Alarcon GS. Impotence in three rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1989; 32: 1341-2
96. Sussman A, Leonard JM. Psoriasis, methotrexate, and oligospermia. Arch Dermatol 1980; 116: 215-7